X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33) 33
diabetes (20) 20
diabetes mellitus (20) 20
female (20) 20
endocrinology & metabolism (19) 19
male (19) 19
type 2 diabetes (19) 19
cardiac & cardiovascular systems (14) 14
middle aged (14) 14
glucose (12) 12
patients (12) 12
adult (11) 11
heart failure (11) 11
risk (11) 11
aged (10) 10
cardiovascular disease (10) 10
diabetes mellitus, type 2 - drug therapy (10) 10
prevalence (10) 10
hypoglycemic agents - therapeutic use (9) 9
mortality (9) 9
sodium (9) 9
association (8) 8
heart diseases (8) 8
insulin (8) 8
metformin (8) 8
outcomes (8) 8
risk factors (8) 8
dapagliflozin (7) 7
diabetes mellitus, type 2 - complications (7) 7
observational study (7) 7
treatment outcome (7) 7
arrhythmias, cardiac - diagnosis (6) 6
cardiopulmonary resuscitation (6) 6
cardiovascular diseases (6) 6
clinical medicine (6) 6
dextrose (6) 6
diabetes therapy (6) 6
drug therapy (6) 6
hypoglycemia (6) 6
inhibitors (6) 6
original (6) 6
united states - epidemiology (6) 6
adults (5) 5
analysis (5) 5
cohort studies (5) 5
critical care medicine (5) 5
death (5) 5
diabetes mellitus, type 2 - blood (5) 5
engineering, biomedical (5) 5
glucose-lowering drugs (5) 5
glycaemic control (5) 5
glycosylated hemoglobin (5) 5
heart attacks (5) 5
heart-failure (5) 5
hemoglobin (5) 5
management (5) 5
mellitus (5) 5
regression analysis (5) 5
studies (5) 5
time factors (5) 5
arrhythmia (4) 4
cardiovascular diseases - prevention & control (4) 4
cardiovascular outcomes (4) 4
chemical vapor deposition (4) 4
clinical trials (4) 4
confidence intervals (4) 4
diabetes mellitus, type 2 - epidemiology (4) 4
dosage and administration (4) 4
electrophysiology (4) 4
emergency medicine (4) 4
events (4) 4
follow-up studies (4) 4
glycated hemoglobin a - analysis (4) 4
heart (4) 4
hospital cardiac-arrest (4) 4
hyperglycemia - prevention & control (4) 4
hypoglycemia - chemically induced (4) 4
hypoglycemia - prevention & control (4) 4
hypoglycemic agents (4) 4
hypoglycemic agents - adverse effects (4) 4
magnetics (4) 4
magnetocardiography (4) 4
medical research (4) 4
original article (4) 4
original articles (4) 4
peripheral vascular disease (4) 4
stroke (4) 4
treatment intensification (4) 4
young adult (4) 4
abridged index medicus (3) 3
accuracy (3) 3
age factors (3) 3
algorithms (3) 3
antidiabetic drug (3) 3
arrhythmias (3) 3
arteriosclerosis (3) 3
blood glucose - drug effects (3) 3
blood glucose - metabolism (3) 3
canagliflozin (3) 3
cardiac arrest (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, obesity & metabolism, ISSN 1463-1326, 2017, Volume 20, Issue 2, pp. 427 - 437
Journal Article
Diabetes, obesity & metabolism, ISSN 1463-1326, 2017, Volume 20, Issue 2, pp. 344 - 351
Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk... 
cardiovascular disease | DPP‐4 inhibitor | type 2 diabetes | diabetes complications | hypoglycaemia | dapagliflozin | DPP-4 inhibitor | REGISTER | SEVERE HYPOGLYCEMIA | MONOTHERAPY | HEART-FAILURE | PREVALENCE | COMBINATION | METFORMIN TREATMENT | INSULIN | DRUGS | ENDOCRINOLOGY & METABOLISM | DPP-4 INHIBITORS | Diabetic Cardiomyopathies - ethnology | Cardiovascular Diseases - ethnology | Follow-Up Studies | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Risk | Diabetes Mellitus, Type 2 - metabolism | Incidence | Hypoglycemia - prevention & control | Cardiovascular Diseases - complications | Diabetes Mellitus, Type 2 - ethnology | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - epidemiology | Diabetic Cardiomyopathies - prevention & control | Female | Glucosides - therapeutic use | Diabetic Angiopathies - prevention & control | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Hyperglycemia - prevention & control | Sodium-Glucose Transporter 2 - metabolism | Kaplan-Meier Estimate | Proportional Hazards Models | Diabetic Angiopathies - ethnology | Sweden - epidemiology | Diabetic Cardiomyopathies - epidemiology | Norway - epidemiology | Denmark - epidemiology | Membrane Transport Modulators - therapeutic use | Diabetic Angiopathies - epidemiology | Aged | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Type 2 diabetes | Heart | Complications and side effects | Comorbidity | Atrial fibrillation | Glucose | Comparative analysis | Risk factors | Heart attack | Dextrose | Diabetes therapy | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Heart attacks | Peptidase | Mortality | Diabetes mellitus | Hypoglycemia | Patients | Fibrillation | Sodium | Diabetes | Cardiovascular diseases | Health risk assessment | Diabetes mellitus (non-insulin dependent) | Heart diseases | Original
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 2010, Volume 122, Issue 16 Suppl 2, pp. S298 - S324
Journal Article
Circulation, ISSN 0009-7322, 07/2017, Volume 136, Issue 3, pp. 249 - 259
Journal Article
BMC medicine, ISSN 1741-7015, 2018, Volume 16, Issue 1, pp. 116 - 12
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 22, pp. 2497 - 2506
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 2018, Volume 20, Issue 8, pp. 1983 - 1987
The multinational, observational CVD‐REAL study recently showed that initiation of sodium‐glucose co‐transporter‐2 inhibitors (SGLT‐2i) was associated with... 
cardiovascular disease | type 2 diabetes | SGLT2 inhibitor | observational study | ENDOCRINOLOGY & METABOLISM | RISK | MECHANISMS | INHIBITORS | REG OUTCOME TRIAL | United States - epidemiology | Myocardial Infarction - epidemiology | Prevalence | Follow-Up Studies | Humans | Middle Aged | Stroke - complications | Male | Risk | Myocardial Infarction - therapy | Comparative Effectiveness Research | Diabetic Cardiomyopathies - prevention & control | Female | Stroke - epidemiology | Diabetic Cardiomyopathies - therapy | Diabetic Angiopathies - prevention & control | Diabetes Mellitus, Type 2 - complications | Insurance, Health | Scandinavian and Nordic Countries - epidemiology | Stroke - therapy | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Stroke - prevention & control | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Diabetic Neuropathies - prevention & control | Medical Records | Proportional Hazards Models | Diabetic Angiopathies - therapy | Myocardial Infarction - complications | Propensity Score | Diabetic Neuropathies - therapy | Diabetic Cardiomyopathies - epidemiology | Intention to Treat Analysis | Diabetic Neuropathies - epidemiology | Diabetic Angiopathies - epidemiology | Myocardial Infarction - prevention & control | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Cohort Studies | Stroke (Disease) | Medical records | Glucose | Drug therapy | Stroke patients | Dextrose | Myocardial infarction | Glucose transporter | Cerebral infarction | Stroke | Heart attacks | Clinical trials | Regression analysis | Patients | Sodium | Diabetes | Health risk assessment | Heart diseases | Brief Report | Brief Reports
Journal Article
Journal Article
Patient preference and adherence, ISSN 1177-889X, 2019, Volume 13, pp. 295 - 307
Journal Article
Diabetes, obesity & metabolism, ISSN 1463-1326, 2019, Volume 22, Issue 1, pp. 66 - 78
Aim To assess glycaemic control and factors associated with poor glycaemic control at initiation of second‐line therapy in the DISCOVER programme. Materials... 
glycaemic control | type 2 diabetes | observational study | Hemoglobin | Glucose | Diabetes | Regression analysis | Diabetes mellitus (non-insulin dependent) | Patients | Index Medicus | Original
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
BACKGROUND Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with... 
heart failure | SEVERE HYPOGLYCEMIA | SULFONYLUREA | death | INITIATION | SGLT-2 inhibitor | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | ALL-CAUSE MORTALITY | ORGANIZATION | JAPANESE HOSPITAL DATABASE | ASIA | LOWER RISK | DPP-4 INHIBITORS | observational studies | CARDIAC & CARDIOVASCULAR SYSTEMS | INSULIN | OUTCOMES | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Glucose | Chemical vapor deposition | Analysis | Dextrose | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Subgroups | Matching | Confidence intervals | Databases | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article